The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

Federico Mosna

DOI: https://doi.org/10.3390/cancers16132359

2024-06-27

Cancers

Abstract:The potential of the immune system to eradicate leukemic cells has been consistently demonstrated by the Graft vs. Leukemia effect occurring after allo-HSCT and in the context of donor leukocyte infusions. Various immunotherapeutic approaches, ranging from the use of antibodies, antibody–drug conjugates, bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cells, and therapeutic infusions of NK cells, are thus currently being tested with promising, yet conflicting, results. This review will concentrate on various types of immunotherapies in preclinical and clinical development, from the point of view of a clinical hematologist. The most promising therapies for clinical translation are the use of bispecific T-cell engagers and CAR-T cells aimed at lineage-restricted antigens, where overall responses (ORR) ranging from 20 to 40% can be achieved in a small series of heavily pretreated patients affected by refractory or relapsing leukemia. Toxicity consists mainly in the occurrence of cytokine-release syndrome, which is mostly manageable with step-up dosing, the early use of cytokine-blocking agents and corticosteroids, and myelosuppression. Various cytokine-enhanced natural killer products are also being tested, mainly as allogeneic off-the-shelf therapies, with a good tolerability profile and promising results (ORR: 20–37.5% in small trials). The in vivo activation of T lymphocytes and NK cells via the inhibition of their immune checkpoints also yielded interesting, yet limited, results (ORR: 33–59%) but with an increased risk of severe Graft vs. Host disease in transplanted patients. Therefore, there are still several hurdles to overcome before the widespread clinical use of these novel compounds.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the key challenges in the treatment of acute myeloid leukemia (AML). Although some progress has been made in the treatment of AML in recent years, the prognosis of many patients is still poor, especially for patients with relapsed or refractory AML. Current standard treatment methods, such as chemotherapy and allogeneic hematopoietic stem cell transplantation (allo - HSCT), although sometimes curable, are also accompanied by serious treatment - related complications.

Specifically, the paper aims to explore how to improve the treatment effect of AML through immunotherapy. Immunotherapy is a new treatment method that uses the patient's own immune system to fight cancer cells. The paper summarizes the main immunotherapy strategies currently under research and evaluates the safety and effectiveness of these methods from the perspective of clinical hematologists. The key topics of discussion include:

1. **Ideal target selection**: The paper explores the characteristics that an ideal antigen for AML immunotherapy should possess, such as high expression in tumor cells, low or no expression in non - tumor cells, and having redundant biological functions. Due to the high heterogeneity of AML, a perfect target has not been found yet.

2. **Monoclonal antibodies, antibody - drug conjugates (ADC) and bispecific T - cell engagers**:
- **Monoclonal antibodies and ADC**: The paper reviews the application of monoclonal antibodies and ADC in the treatment of AML and their clinical results. For example, Gemtuzumab Ozogamicin, as an ADC, has been included in the standard treatment protocol.
- **Bispecific T - cell engagers**: The paper details the research progress of various bispecific T - cell engagers, such as AMG 330, AMG 673, Flotetuzumab, etc. These drugs have shown certain efficacy in clinical trials, but also face some challenges, such as cytokine release syndrome (CRS) and bone marrow toxicity.

3. **CAR - T cell therapy and other immune checkpoint inhibitors**: The paper also discusses the application of CAR - T cell therapy and immune checkpoint inhibitors in the treatment of AML. These methods have achieved significant treatment effects in some cases, but also have problems such as toxicity and drug resistance.

In conclusion, the main objective of the paper is to summarize and evaluate the potential of various immunotherapies in the treatment of AML, providing clinicians with the latest, critically - evaluated information to promote the development of more precise oncology treatment strategies.